| Symbol
| VTN
| contributors: mct - updated : 30-11-2016
|
| HGNC name
| vitronectin (serum spreading factor, somatomedin B, complement S-protein)
|
| HGNC id
| 12724
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
|
|
| --over
|
|
in sera from patients with Joint hypermobility syndrome (JHS)  | |
| Susceptibility
|
to vascular disease (chronic or acute myocardial infarctus , or deep venous thrombosis) |
| Variant & Polymorphism
SNP
| rs2227721 was associated with susceptibility to vascular disease |
| 
|
Candidate gene
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | bone | | |
| may serve as a potential therapeutic target in osteosarcoma | | cancer | digestive | liver | |
| inhibition of VTN could potentially be applied for the treatment of hepatocellular carcinoma | | cancer | reproductive | ovary | |
| could represent a target for the development of anti-adhesive strategies to impede ovarian cancer dissemination |
| | | |